Retina specialists who use compounded bevacizumab off-label to treat wet age-related macular degeneration are being warned that counterfeit vials of the cancer drug have turned up in oncology practices in the United States.
Analyses of 24-month data from the two pivotal phase III trials investigating a proprietary fluocinolone acetonide-releasing intravitreal insert for the treatment of diabetic macular edema generated positive results that are the basis of filing a new drug application with the FDA.
Concern about potential long-term toxicity associated with use of mitomycin-C is driving researchers to identify new pharmacologic approaches for managing haze formation after PRK.
Results from an interim analysis of a phase II study show fenretinide is well tolerated and exhibits promising biological activity in slowing lesion growth in patients with advanced geographic atrophy associated with age-related macular degeneration.
Preliminary results from a phase 1 safety and tolerability study show no dose-limiting toxicity so far in patients treated with intravitreal injections of volociximab in combination with anti-VEGF therapy for neovascular age-related macular degeneration.
Ranibizumab for the treatment of macular edema associated with central retinal vein occlusion demonstrated rapid and sustained improvement as early as 7 days after the start of treatment through 6-month interim analysis.
Compared with sham injections, monthly injections of 0.3 or 0.5 mg of ranibizumab significantly reduced macular edema and improved best-corrected visual acuity in patients with branch retinal vein occlusion.
A nationwide shortage of erythromycin ophthalmic ointment is causing some ophthalmologists to try alternative antibiotic therapies to treat superficial ocular infections.
Twice-daily dosing of bepostastine besilate ophthalmic solution 1.5% was found to be safe, with minimal adverse events, in a randomized, double-masked, 6-week safety study including two groups of healthy pediatric patients.
The recent FDA approval of ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis brings to U.S. ophthalmologists an important advance in topical antiviral therapy for a condition that is the leading infectious cause of corneal blindness in the United States.